Newer treatments for advanced hepatocellular carcinoma
The Korean Journal of Internal Medicine
;
: 149-155, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-106000
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options are needed for patients with advanced HCC. The current standard treatment for patients with advanced HCC, according to the Barcelona Clinic Liver Cancer staging system, is the multikinase inhibitor sorafenib. Other alternative therapies are required, due to the limited treatment response to, and tolerance of, this molecular target agent. Clinical trials of hepatic artery infusion chemotherapy, radioembolization, and multimodal treatments have shown favorable results in advanced HCC patients. This article introduces new treatment modalities for advanced HCC and discusses future therapeutic possibilities.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Compostos de Fenilureia
/
Infusões Intra-Arteriais
/
Transdução de Sinais
/
Resultado do Tratamento
/
Niacinamida
/
Terapia Combinada
/
Carcinoma Hepatocelular
/
Compostos Radiofarmacêuticos
/
Inibidores de Proteínas Quinases
/
Embolização Terapêutica
Limite:
Humanos
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS